Afinitor contains the active ingredient everolimus and may not be safe to take during pregnancy and breastfeeding. Keep reading for specific information about reproductive health and Afinitor.

Afinitor (everolimus) was being investigated as a treatment for patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or intolerance to sorafenib.

Afinitor (everolimus) is a prescription drug that’s used to treat some types of cancer, seizures, and certain tumors. This drug can interact with other medications and some supplements.

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The new decision means that Afinitor will be ...

Patients with previously treated advanced clear cell renal cell carcinoma (RCC) — a type of kidney cancer — experienced improvements in progression and response via treatment with Welireg (belzutifan) ...

While Welireg (belzutifan) has outperformed Afinitor (everolimus) in OS at 12 months and 24 months, the results have not achieved statistical significance. The OS gap between Welireg and Afinitor ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Review the side-effects of Everolimus as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Merck (MSD) has secured US Food and Drug Administration (FDA) approval for Welireg (belzutifan), indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Patients who have ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...